Multiple Myeloma
Conference Coverage
Durable responses with anti-BCMA CAR T-cell for multiple myeloma
Seventy-two percent of patients with relapsed/refractory multiple myeloma had ongoing responses at the time of data cutoff in the CARTITUDE-1...
Conference Coverage
COVID-19–related outcomes poor for patients with hematologic disease in ASH registry
From the Journals
Circulating miRNA could be a potential biomarker for early diagnosis of MM
A meta-analysis found that using circulating microRNAs had high sensitivity and specificity in the early diagnosis of multiple myeloma.
Conference Coverage
Home care for bortezomib safe and reduces hospital visits in myeloma patients
From the Journals
Socioeconomic factors affect survival of multiple myeloma patients
From the Journals
Older adults with multiple myeloma face heavy burden of care
From the Journals
Initial response to novel agents preps MM patients for favorable transplant outcomes
Triplet induction outperformed doublet in early outcomes, but later outcome differences were not statistically significant.
Conference Coverage
Survey quantifies COVID-19’s impact on oncology
Oncologists detail how COVID-19 has impacted care, caregivers, continuing medical education, and clinical trials.
From the Journals
Statins linked to improved survival in multiple myeloma
From the Journals
Age, other risk factors predict length of MM survival
From the Journals
Elotuzumab-based therapy may benefit post-transplant response in multiple myeloma